Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “TYRAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1968

The action of tyramine on the rabbit ear artery.

1. The vasoconstrictor potency of extraluminal tyramine on the isolated perfused rabbit ear artery is considerably greater than that of intraluminal tyramine.2. Chronic denervation, which caused the noradrenergic storage structures in the medial-adventitial border of the artery to disappear, reduces the potency of extraluminal tyramine more than that of intraluminal tyramine so that the difference in potency for the two routes of administration tends to disappear. Cocaine exerts a greater inhibitory effect on responses to extraluminal tyramine than on those to intraluminal tyramine.3. It is concluded that the indirect component plays a more prominent part in the responses to extraluminal tyramine than in those to intraluminal tyramine. This conclusion is supported by analysis of the diphasic response of the artery to intraluminal injection of tyramine under perfusion conditions which permit intraluminal fluid to mix with the extraluminal fluid. Evidence is presented that the first phase of the response is mediated by intraluminal tyramine, and the second phase by extraluminal tyramine.

Animals↗
PubMed2006

Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.

The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on-treatment tyramine pressor doses. The tyramine sensitivity factor value following 9 days of treatment with the selegiline transdermal system was 1.85 +/- 0.10. Extended treatment, 33 days, produced a small, clinically non-meaningful increase in this value. The tyramine sensitivity factor for the selegiline transdermal system was similar to that following treatment with 10 mg/d of oral selegiline capsules but more than 20 times less than observed during tranylcypromine treatment. A larger increase in the tyramine sensitivity factor was observed following extended selegiline transdermal system treatment at a higher dose (12 mg/24 h), which was significantly decreased following coadministration of tyramine capsules with a meal. These results suggest a wide tyramine safety margin for the selegiline transdermal system and provide evidence that the 6-mg/24-h selegiline transdermal system can be administered safely without dietary tyramine restrictions.

Administration, Cutaneous↗
PubMed2004

The biogenic amine tyramine modulates the adherence of Escherichia coli O157:H7 to intestinal mucosa.

The environmental factors that influence the ability of Escherichia coli O157:H7 to attach to the intestinal mucosa are incompletely understood. In the present study, the ability of one of the most common biogenic amines present in food, tyramine, to influence the ability of E. coli O157:H7 to adhere to murine cecal mucosa was examined. Ex vivo full-thickness sheets of murine cecum were mounted in Ussing chambers, which preserved the enteric nervous system innervation of the luminal epithelia and thereby allowed us to achieve a closer approximation of bacterial adherence than would be encountered in vivo. After exposure of the luminal aspect of the cecum to tyramine, E. coli O157:H7 was added for 90 min. The cecal tissue was then removed and washed, and adhered E. coli O157:H7 was enumerated using a selective medium. Tyramine significantly increased E. coli O157:H7 adherence to cecal mucosa when compared to that of controls. The 50% effective concentration of tyramine was 92.6 microM. Specific adrenergic antagonists were then employed to examine whether the effect of tyramine was mediated through alpha- or beta-adrenergic receptors on the intestinal tissue. Pretreatment of tissues with either the alpha-adrenergic receptor antagonist phentolamine or the beta-adrenergic receptor antagonist propranolol prevented the action of tyramine. Measurement of active transepithelial ion transport and ionic permeability in the cecal sheets before and after the addition of tyramine and E. coli O157:H7 did not show any impairment of tissue viability or transepithelial conductance. Further, tyramine did not influence either the growth of E. coli O157:H7 or the expression of the intimin attachment factor. The present findings suggest that biogenic amines, such as tyramine, present within the food matrix influence host susceptibility to E. coli O157:H7 infection.

Animals↗
PubMed1980

[Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].

The inhibition by chlorgyline and deprenyl of deamination of tyramine, i. e. substrate of two forms of monoamine oxidase (MAO) A and B, by fragments of rat liver mitochondrial membrane and the effects of competitive reversible inhibitors of the MAO activity, e. g. 4-ethylpyridine, benzyl alcohol, O-benzyl-hydroxylamine and 2-oxyquinoline, on this process were studied. It was shown that all the inhibitors used sharply increase the inhibiting effect of chlorgyline on tyramine deamination, the degree of the stimulating effect being the same irrespective of whether the inhibitors are added to the samples before or after a 30-min preincubation of chlorgyline with the enzyme at 23 degrees, i. e. after the onset of irreversible inhibition. The stimulating effect is due to the independent action of two inhibitors on the two different sites of the MAO active center: chlorgyline--on the isoalloxazine ring of FAD, that of 4-ethylpyridine, benzyl alcohol, O-benzylhydroxylamine, 2-oxyquinoline, respectively, on the hydrophobic region involved in tyramine binding. In similar experiments with deprenyl all the competitive inhibitors used, when added to the samples after a 30-min incubation of the inhibitor with the enzyme at 23 degrees, remove the inhibiting effect of deprenyl on tyramine deamination. The decrease of the inhibiting effect of deprenyl is indicative of an existence of competitive interactions between deprenyl and the above-mentioned compounds and of the reversible inhibition by deprenyl of tyramine deamination under the given experimental conditions. The data obtained revealed the differences in the type and mechanism of action of chlorgyline and deprenyl on tyramine deamination and showed that these inhibitors act on different sites of the MAO active center, responsible for tyramine oxidation. Chlorgyline blocks primarily the "flavin moiety" of the MAO molecule, essential for the catalytic act, while the effect of deprenyl is directed to the hydrophobic part of the enzyme active center essential for the enzyme binding to tyramine. In this case the irreversible inhibiting effect is achieved at a slower rate and the reversibility of tyramine oxidation by deprenyl is maintained for a longer period of time than the chlorgyline inhibition of deamination of this amine.

Animals↗
PubMed2002

Brain tyramine and reproductive states of workers in honeybees.

To explore the role of tyramine in the transformation of reproductive states of honeybee workers, brain levels of tyramine and N-acetyltyramine were measured in both normal and queenless workers. Queenless workers had higher tyramine levels and lower N-acetyltyramine levels than normal workers did. Intermediate reproductive workers that were transferred into a normal colony from a queenless colony had intermediate levels of tyramine and N-acetyltyramine. Elevation of tyramine in the queenless workers occurred at an earlier adult stage than elevation of dopamine. Tyramine levels in intermediate reproductive workers returned to the levels seen in normal workers, but dopamine levels in intermediate reproductive workers remained elevated at the same level as in queenless workers. Thus, brain tyramine may be regulated by the colony condition with or without a queen. Injection of an amine uptake inhibitor, reserpine, depleted tyramine and elevated N-acetyltyramine. Distributions of tyramine and dopamine within the brain were distinctively different, whereas distributions of N-acetyltyramine and N-acetyldopamine were similar, suggesting that each functional amine is stored in specific neurosecretory cells and released to the relevant receptor sites but that metabolism into each N-acetylmetabolite is determined by diffusion.

Journal Article↗
PubMed1963

The action of tyramine on the dog isolated atrium.

It has been confirmed that tyramine has positive inotropic and chronotropic actions on the dog isolated atrium. These responses were incompletely and reversibly inhibited by cocaine, but completely and irreversibly blocked by phenoxybenzamine. Blockade of the atrial beta-receptors by dichloroisoprenaline could be overcome by noradrenaline and by larger doses of tyramine. With the aortic strip of the reserpinized rabbit for assay, tyramine was shown to release a vasoactive material from the dog atrium whose receptors were blocked by dichloroisoprenaline. The use of an antihistamine and an anti-5-hydroxytryptamine agent (cyproheptadine) appeared to exclude the possibility that the effect was due to the release of histamine or 5-hydroxytryptamine from the atrium by tyramine. Further observations of the action of the vasoactive material on the guinea-pig ileum and on the rat fundal strip strongly suggested that the material was a catechol amine. It was concluded that under these conditions tyramine acts by liberating catechol amines from storage sites so that the amines are free to act at receptor sites. The behaviour of the atrium to tyramine in the presence of cocaine or of phenoxybenzamine suggests that the liberation of catechol amines by tyramine differs from the release due to adrenergic nerve stimulation. It is suggested that, after an infusion of tyramine, there is a much slower release of catechol amines than after stimulation of adrenergic nerves.

Amines↗
PubMed1981

A chemical ionization gas chromatographic mass spectrometric assay for octopamine and tyramine in rat brain.

A method has been developed for the quantitation of the putative phenolamine neurotransmitter octopamine, and its precursor tyramine, in brain tissue. The procedure employs methane chemical ionization of the pentafluoropropionate derivatives of octopamine and tyramine together with the use of deuterated internal standards and selected ion monitoring. Deuterated analogues of octopamine and tyramine are added to brain homogenates in aqueous perchloric acid and ion exchange is used to isolate the brain amines. The method is capable of measuring 20 pg of octopamine and tyramine. The measured concentration (ng g-1 wet tissue) of octopamine and tyramine in rat brain was as follows: whole brain (less cerebellum) (0.6 and 2.2); hypothalamus (3.2 and tyramine value not statistically significant); striatum (0.5 and 11.8) and cortex (0.6 and 1.0). Administration of pargyline resulted in an increase (around ten-fold) in octopamine and tyramine concentration in all the above brain regions. In contrast alpha-methyltyrosine produced only a small increase (50%) in the concentration of tyramine in the striatum.

Animals↗
PubMed2004

Tyramine and octopamine have opposite effects on the locomotion of Drosophila larvae.

Biogenic amines are believed to play important roles in producing behaviors. Although some biogenic amines have been extensively studied in both vertebrates and invertebrates, little is known about the effects of trace amines like tyramine and octopamine. We investigated how trace amines affect behaviors using quantitative morphometric methods on Drosophila Tbetah(nM18) and iav(N) mutants that have altered levels of tyramine and octopamine. Locomotion of wild-type and mutant third instar larvae was analyzed using Dynamic Image Analysis System (DIAS) software. We found that Tbetah(nM18) mutants, with elevated tyramine levels and reduced octopamine levels, had a severe locomotion phenotype. Mutant larvae spent much more time in pausing episodes than wild-type larvae and displayed a reduction in speed and linear translocation. The locomotion phenotype was partially rescued by feeding Tbetah(nM18) larvae octopamine, an effect that could be nullified with simultaneous feeding of tyramine. Feeding Tbetah(nM18) larvae yohimbine, an agent that inhibits the activity of Drosophila tyramine receptors, also improved some locomotion parameters. Feeding both octopamine and yohimbine further improved rescue efficiency. Simultaneously reducing the octopamine and tyramine levels as in iav(N) larvae, in contrast, led to a less severe behavioral phenotype than that of Tbetah(nM18) mutants. Feeding iav(N) larvae either tyramine or octopamine exerted only a minor improvement in locomotion. These results suggest that tyramine and octopamine have opposite effects on Drosophila larval locomotion regulation and that a balance between the two is important in producing normal behavior.

Animals↗
PubMed1999

[3H]Tyramine uptake by rat liver slices.

Rat liver slices were employed as experimental model to characterise the system involved in the transport process which participates in liver tyramine uptake. The uptake of 0.4 micromol l-1of [3H]tyramine by rat liver slices was linear from 5 min up to the end of incubation. At 15 min the uptake was 4.58+/-0.18 pmol mg-1protein. The accumulation of [3H]tyramine was sensitive to temperature (69. 3+/-4.0% inhibition at 0 degrees C, P<0.001), to sodium omission replaced by 150 mmol l-1Tris or 110 mmol l-1Tris+40 mmol l-1choline (27.6+/-6.0%, P<0.01, and 24.6+/-3.8% inhibition, P<0.01, respectively), and the inhibition of Na+-K+-adenosine triphosphatase by 150 micromol l-1ouabain (20.4+/-2.6% decrease, P<0.01). Uptake of [3H]tyramine was cocaine- (10 micromol l-1) and desipramine- (1 micromol l-1) dependent (32.2+/-6.4%, P<0.05, and 31.6+/-4.0% inhibition, P<0.05, respectively). Uptake of [3H]tyramine in rat liver slices was not modified by 30 micromol l-1isoprenaline, 30 micromol l-1corticosterone, 30 micromol l-1normetanephrine and noradrenaline up to 4 micrometers at higher noradrenaline concentrations tyramine transport was diminished (P<0.05). Results achieved by incubation with increasing tyramine concentrations indicate that at the micromolar level hepatic uptake occurs by a combined passive diffusion and transport-mediated mechanism, whereas at greater tyramine concentrations passive transport predominates. These results suggest that both simple diffusion and a transport-mediated mechanism are involved in this uptake from hepatocytes, which presents features similar to those described for type 1 non-neuronal uptake systems.

Adrenal Cortex Hormones↗
PubMed1987

Release of neuropeptide Y (NPY) induced by tyramine in the isolated vas deferens of rat.

The effect of tyramine on the isolated vas deferens of rats was investigated. Tyramine induced a dose-dependent contraction which was blocked by phentolamine and disappeared in adrenergic denervated tissues. In the presence of an antiserum to neuropeptide Y (NPY), the contraction induced by concentrations of tyramine greater than 10 microM was markedly increased. In addition to inducing the release of 3H-norepinephrine (NE), tyramine evoked a concentration-dependent efflux of NPY-like immunoreactivity (NPY-LI) from synaptosomal preparations. This action was not modified either by the removal of calcium ion from the medium or by the pretreatment with tetrodotoxin (0.5 microM). Desipramine suppressed the NPY-LI release induced by tyramine apparently by the inhibition of the uptake of tyramine is suggested by the significant positive correlation between the reduction of 14C-tyramine uptake and the inhibition of NPY-LI release induced by desipramine (r = 0.946). Therefore, we suggest that tyramine does induce the release of NPY from rat vas deferens, in addition to effecting NE secretion.

Animals↗
PubMed1986

The effect of raphé nuclei lesions on striatal tyramine concentration and dopamine turnover in the rat.

This is an investigation of the effects of electrolytic lesions (1 mA, 10s, anodal) on the median and dorsal raphé nuclei of Wistar rats on the striatal concentrations of p-tyrosine, p-tyramine, m-tyramine, DA, DOPAC, and HVA. The extent of the lesions was estimated in terms of the depletion of 5-hydroxytryptamine and 5-hydroxyindole acetic acid as well as histological examination of the lesioned area. The results show that the raphé nuclei lesions increased rat striatal levels of DOPAC and HVA while levels of DA were unaffected, an effect that was observed within the first day after the lesions were made. The increases in DOPAC and HVA were accompanied by a reduction in striatal p-tyramine and an increase in m-tyramine. The results further support the existence of a reciprocal relationship between p- and m-tyramine concentrations and dopamine metabolism. Previous experiments have demonstrated depletion of p-TA following nigral lesions. The present results are, therefore, important in relation to tyramine distribution in brain. The p- and m-tyramine concentrations were not reduced at 7 days after the raphé nuclei lesions indicating that if the striatal tyramine-containing neurons exist, they do not originate in or pass through the dorsal or median raphé nuclei.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1984

Responsiveness to tyramine in isolated lung parenchymal strip of guinea-pig and rat.

The effects of alpha/beta-adrenoceptor agonists in isolated lung parenchymal strip are well characterized but information related to indirectly acting sympathomimetic agents is scarce. In the present study the response to tyramine was analyzed in lung strips from guinea-pig and rat. Tyramine elicited a dose-related contraction of the lung strip with an EC50 of 1.12 X 10(-4) M in the guinea-pig and 4.28 X 10(-4) M in the rat. Incubation with propranolol did not modify the tyramine-induced contraction but blocked the relaxation which occasionally appeared at low concentrations of tyramine. No tachyphylaxis to tyramine was detected. Cocaine (3 X 10(-5) M) and reserpine significantly increased the EC50 values of tyramine. In reserpine-treated animals, phentolamine (both animal species), clemizole (guinea-pig) and methysergide (rat) displaced to the right the concentration-response curve to tyramine but the dose ratios were significantly lower than those obtained for their specific agonists. These results suggest that in addition to the adrenergic component (catecholamine release and direct alpha-adrenoceptor activation) there is an important contribution of other receptor systems such as histamine (guinea-pig) and 5-hydroxytryptamine (rat) to the contractile response to tyramine in lung tissue.

Acetylcholine↗
PubMed1994

Interaction of MAO inhibitors and dietary tyramine: a new experimental model in the conscious rat.

The aim of this study was to assess a new model for tyramine-induced pressor effects in the rat. The predictivity of the test is improved by simulating the real clinical situations where tyramine is ingested with food and beverages containing the amine. The pressor effect was investigated after oral administration of tyramine in a feed preparation or in a water solution by continuously recording blood pressure just above the aorta junction via a left-carotid catheter. The response was quantified by measurement of peak systolic blood pressure and as the percentage of tyramine-sensitive rats (TSR) in which the maximal pressor response to the amine was higher than 30 mm Hg (clinical risk threshold). Tyramine elicited, after oral administration (by gavage), a statistically significant dose-dependent increase in blood pressure from the dose of 10 mg/kg in solution (i.e. 23 +/- 3 mm Hg, N = 36) and 40 mg/kg in feed preparation (i.e., 20 +/- 2 mm Hg, N = 26). Almost all rats showed a systolic blood pressor increase higher than 30 mm Hg after oral administration of tyramine at a dose of 80 mg/kg p.o. in solution (TSR = 96%). Administration of tyramine in food (80 mg/kg) significantly delayed the time of the peak blood pressure (13 +/- 2 min instead of 7 +/- 0.5 min in solution, p < .001). Under these conditions, the tyramine threshold dose of TYR 30 (dose inducing an average response equivalent to the clinical risk threshold) was 14 mg/kg p.o. in solution and 67 mg/kg p.o. in feed preparation, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1998

Histamine and tyramine degradation by food fermenting microorganisms.

Microorganisms suitable for food fermentation were examined with regard to their potential to degrade histamine and tyramine. Out of 64 lactic acid bacteria evaluated in this study, 27 degraded histamine and one tyramine, respectively, with low activity. Among 32 strains of Brevibacterium linens and coryneform bacteria, 21 exhibited histamine and tyramine oxidase activity. None of 20 strains of Staphylococcus carnosus tested degraded histamine or tyramine. One strain out of nine strains of Geotrichum candidum degraded tyramine slightly. Among 44 strains of Micrococcus sp. examined, 17 degraded either one or two biogenic amines. In this study Micrococcus varians (M. varians) LTH 1540 exhibited the highest tyramine oxidase activity of all strains tested and was therefore investigated in detail. The enzyme was found to be located in the cytoplasm and was not membrane bound. The reaction end product p-hydroxyphenyl acetic acid was detected by HPLC analysis. An activity staining for the amine oxidase in a native polyacrylamide gel based on the formation of H2O2 during amine oxidation was developed. Resting cells of the strain exhibited optimal tyramine oxidase activity at a pH of 7 at 37-40 degrees C. The enzyme in the cell free extract had a pH optimum between 7-8. The enzyme activity was decreased by NaCl, glucose and hydralazine. Phenylethylamine and tryptamine were oxidized at lower concentrations than tyramine. The potential for amine degradation was not found to be associated with that of formation of biogenic amines, as 23 microorganisms with the ability to metabolise biogenic amines exhibited no decarboxylase activity toward histidine, tyrosine, phenylalanine, lysine or ornithine.

Fermentation↗
PubMed2000

A tyramine receptor gene mutation causes a defective olfactory behavior in Drosophila melanogaster.

We characterized molecular profiles of a new olfactory mutant line, honoka (hono), which was found among 500 viable P-element insertion lines screened first by 5-bromo-4-chloro-3-indrolyl-beta-D-galactopyranoside (X-gal) staining on the third segment of the antenna, and then by behavioral assays to several pure chemicals. The behavioral responses of hono mutants to repellents such as ethyl acetate (EA), benzaldehyde (BZ) and 4-methylcycrohexanol (MCH), were reduced compared with those of a control strain. The location of the P-element insertion was determined to be about 100bp) upstream of the first exon of the tyramine receptor gene. The level of 3.6kb tyramine receptor mRNA expression was reduced in hono compared with that of wild-type flies. The tyramine receptor cDNA hybridized to the chromosomal division 79C-D, the same locus as the P-element insertion point in hono, and not to 99A-B, previously reported by Arakawa et al. (1990. Neuron 2, 343-354). Electrophysiological responses to octopamine and tyramine were examined by measuring the excitatory junctional potential (EJP) amplitude from larval body-wall muscles of the hono mutant. The hono was impaired with responding to tyramine, while displaying normal response to octopamine. These results indicate that tyramine has a functional role in the Drosophila olfactory system as a neurotransmitter or a neuromodulator, and hono is the first tyramine receptor mutant. This study provides the first step toward understanding of the molecular genetics of tyramine-mediated neural functions in Drosophila.

Acetates↗
PubMed1989

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

The effect of the monoamine oxidase inhibitor selegiline on tyramine metabolism and intravenous and oral tyramine pressor sensitivity was studied in healthy subjects. After oral doses of tyramine, which caused systolic blood pressure to increase by 30 mm Hg, we determined plasma concentrations of p-hydroxyphenylacetic acid (HPAA) and of conjugated and unconjugated tyramine. When 20 mg/day of selegiline was administered, the AUCspec of HPAA decreased from 86% to 64% and the AUCspec of conjugated tyramine increased from 13% to 35% of the sum of total tyramine and HPAA. Pressor sensitivity was enhanced more with oral administration of tyramine than with intravenous administration of tyramine. After the drug was discontinued, initial values were reached within 4 days (one subject) and 2 weeks (two subjects). Fifty-five percent of the selegiline dose was eliminated in urine as amphetamine and methamphetamine. The findings support the assumption that selegiline does not selectively inhibit monoamine oxidase-B (MAO-B) when administered in doses of 20 mg/day and higher.

Administration, Oral↗
PubMed1976

The conjugation of tyramine with sulphate by liver and intestine of different animals.

Tyramine was conjugated with sulphate by extracts of monkey intestine and livers of monkey, rat, mouse, guinea pig and man. The activity measured in monkey intestine was almost three times that of monkey liver. Labelled tyramine sulphate synthesized from [14C] tyramine, [3H] tyramine or Na235SO4, on acid hydrolysis, released its radioactive precursor. Liver extracts of monkey, rat, mouse and guinea pig synthesized respectively 145,66,21 and 6 pmol of [14C] tyramine sulphate/min per mg of protein. Except with the monkey, intestine exhibited very low activity. trans-2-Phenylcyclopropylamine, a monoamine oxidase inhibitor, was added as a routine to the enzyme preparation, as its omission resulted in the production of p-hydroxyphenylacetic acid in appreciable amounts. This oxidative deamination of tyramine, however, did not decrease the sulpho-conjugation of tyramine. The low Km (9.1 muM) of sulphotransferase for tyramine is probably responsible.

Animals↗
PubMed1998

Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.

AIMS: To examine the feasibility of using the human iris in vivo for the assessment of the interaction between tyramine and monoamine oxidase (MAO) inhibitors. To examine the relative roles of the two forms of MAO in terminating the response to sympathomimetic amines in the iris, by comparing the effects of single oral doses of moclobemide, a selective MAO-A inhibitor, and selegiline, a selective MAO-B inhibitor, on mydriatic responses to tyramine. METHODS: Twelve healthy male volunteers participated in three monthly sessions, each associated with ingestion of one capsule (moclobemide 450 mg, selegiline 10 mg, or placebo), according to a double-blind, balanced, cross-over design. Tyramine hydrochloride eye-drops (75 mM, 2 x 10 microl) were instilled three times in the left conjuctival sac at 40 min intervals. Pupil diameter was monitored with a binocular infrared television pupillometer before and for 4.5 h after ingestion of the capsule. The pupillary response to tyramine was expressed as the area under the pupil diameter x time curve (arbitrary units). A blood sample was taken before and 2 h after ingestion of the capsule, for the assay of platelet MAO-B activity, and plasma 3,4-dihydroxyphenylglycol (DHPG) concentration, an index of MAO-A activity. Platelet MAO activity was assayed radiochemically, using [14C]-phenylethylamine as substrate, and plasma DHPG by high performance liquid chromatography (h.p.l.c.). The results were analysed using analysis of variance with repeated measures, followed by Bonferroni's corrected t-test, using a significance criterion of P < 0.05. RESULTS: Both moclobemide and selegiline, compared with placebo, caused significant miosis in the right (untreated) eye. The changes in pupil diameter (mm +/- s.e. mean) from the pretreatment measurement were: placebo -0.09 +/- 0.07, moclobemide -0.52 +/- 0.09, selegiline -0.26 +/- 0.1. The mydriatic response to tyramine was potentiated by moclobemide, compared with the response recorded in the presence of placebo. The responses to tyramine (arbitrary units +/- s.e. mean) were: placebo 77.08 +/- 11.65, moclobemide 140.25 +/- 18.9, selegiline 72.75 +/- 12.35. Both moclobemide and selegiline significantly reduced platelet MAO activity, compared with placebo. The changes in platelet MAO activity (nmol h(-1) mg(-1) protein +/- s.e. mean) from the pretreatment level were: placebo 0.5 +/- 0.62, moclobemide -6.7 +/- 0.66, selegiline -17.7 +/- 0.87. Moclobemide significantly reduced plasma DHPG concentration, compared with placebo. The changes in plasma DHPG concentration (nmol l(-1) +/- s.e. mean) from the pretreatment level were: placebo -0.01 +/- 0.24, moclobemide -4.98 +/- 0.32, selegiline -0.51 +/- 0.26. CONCLUSIONS: The potentiation of tyramine-evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO-A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals. The lack of effect of selegiline on tyramine-evoked mydriasis argues against a role of MAO-B in terminating the effects of sympathomimetic amines in the iris. The effects of the two drugs on platelet MAO activity and plasma DHPG concentration are in agreement with previous reports and consistent with the relative selectivity of moclobemide for MAO-A and of selegiline for MAO-B. The miosis caused by the two MAO inhibitors is likely to be due to a central sympatholytic action of the drugs.

Adult↗